This database contains 370 studies, archived under the term: "treatment outcome"
Click here to filter this large number of results.
Continuous positive airway pressure deepens sleep in patients with Alzheimer’s disease and obstructive sleep apnea
Cooke, Jana R.,
Ancoli-Israel, Sonia,
Liu, Lianqi,
Loredo, Jose S.,
Natarajan, Loki,
Palmer, Barton S.,
He, Feng,
Corey-Bloom, Jody
Objective: Patients with Alzheimer’s disease (AD) and obstructive sleep apnea (OSA) experience disrupted sleep. This study examined the effect of continuous positive airway pressure (CPAP) on sleep parameters in AD patients with OSA.; Methods: A randomized placebo-controlled trial of 3 weeks of therapeutic CPAP (tCPAP) vs. 3 weeks placebo CPAP (pCPAP) followed by 3 weeks […]
An exploratory cluster randomized controlled trial of group exercise on mobility and depression in care home residents
Brittle, Nicola,
Patel, Smitaa,
Wright, Christine,
Baral, Sabrina,
Versfeld, Pam,
Sackley, Catherine
Objective: To investigate the feasibility, acceptability and potential efficacy of group exercise for residents in care homes.; Design: Exploratory cluster randomized controlled trial.; Setting: Five randomly selected care homes in South Birmingham, UK.; Participants: Fifty-six care home residents (mean age 84.5, 71% female), 39 (70%) with cognitive impairments.; Intervention: Two homes (n = 28) were […]
Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer’s disease: a 3-year follow-up longitudinal study
Angelucci, Francesco,
Bernardini, Sergio,
Gravina, Paolo,
Bellincampi, Lorenza,
Trequattrini, Alberto,
Di Iulio, Fulvia,
Vanni, Diego,
Federici, Giorgio,
Caltagirone, Carlo,
Bossù, Paola,
Spalletta, Gianfranco
Although the etiology of psychotic symptoms (hallucinations and delusions) in Alzheimer’s disease is still not known, alterations in serotonergic neurotransmission have been proposed. In a 3-year follow-up study, we evaluated the association of serotonin (5-HT) receptor 5-HT2a 102T/C polymorphism (allelic variants CC, CT and TT) with psychotic symptom severity and response to treatment with atypical […]
Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer’s disease patients treated with the neurotrophic agent cerebrolysin
Alvarez, X. Anton,
Sampedro, Carolina,
Cacabelos, Ramon,
Linares, Carlos,
Aleixandre, Manuel,
García-Fantini, Manuel,
Moessler, Herbert
According to current scientific knowledge, excess tumour necrosis factor-α (TNF-α) and low insulin-like growth factor-I (IGF-I) are pathogenic-risk factors that constitute therapeutic targets for Alzheimer’s disease (AD). Changes in serum TNF-α, total and dissociable IGF-I levels were determined by ELISA in 207 AD patients completing a 24-wk, double-blind, placebo-controlled trial to evaluate the effects of […]
Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer’s disease: a prospective, observational study
Santoro, Aurelia,
Siviero, Paola,
Minicuci, Nadia,
Bellavista, Elena,
Mishto, Michele,
Olivieri, Fabiola,
Marchegiani, Francesca,
Chiamenti, Andrea Maria,
Benussi, Luisa,
Ghidoni, Roberta,
Nacmias, Benedetta,
Bagnoli, Silvia,
Ginestroni, Andrea,
Scarpino, Osvaldo,
Feraco, Emidio,
Gianni, Walter,
Cruciani, Guido,
Paganelli, Roberto,
Di Iorio, Angelo,
Scognamiglio, Mario,
Grimaldi, Luigi Maria Edoardo,
Gabelli, Carlo,
Sorbi, Sandro,
Binetti, Giuliano,
Crepaldi, Gaetano,
Franceschi, Claudio
Acetylcholinesterase inhibitors (AChEIs) have been used to improve cognitive status and disability in patients with mild to moderate Alzheimer’s disease (AD). However, while the efficacy of AChEIs (i.e. how they act in randomized controlled trials) in this setting is widely accepted, their effectiveness (i.e. how they behave in the real world) remains controversial. To compare […]
Plasma concentration of donepezil to the therapeutic response of Alzheimer’s disease in Taiwanese
Yang, Yuan-Han,
Wu, Shey-Lin,
Chou, Mei-Chuan,
Lai, Chiou-Lian,
Chen, Su-Hwei,
Liu, Ching-Kuan
Donepezil has been approved for the treatment for mild-to-moderate Alzheimer’s disease (AD), but the therapeutic response rate varies from 20 to 60%. A higher oral dosage was suggested to have a better therapeutic response in reported results, but the plasma concentration of donepezil was not examined with respect to the therapeutic outcomes in those studies. […]
Effect of music on pain for home-dwelling persons with dementia
The purpose of this study was to investigate the effect of music on pain for home-dwelling persons with dementia. A quasiexperimental design was used. Fifteen subjects listened to their preferred music for 30 minutes before peak agitation time, for 2 days per week, followed by no music for 2 weeks. The process was repeated once. […]
Hospice use and outcomes in nursing home residents with advanced dementia
Objectives: To identify characteristics of nursing home (NH) residents with advanced dementia and their healthcare proxies (HCPs) associated with hospice referral and to examine the association between hospice use and the treatment of pain and dyspnea and unmet needs during the last 7 days of life.; Design: Prospective cohort study.; Setting: Twenty-two Boston-area NHs.; Participants: […]
Errorless practice as a possible adjuvant to donepezil in Alzheimer’s disease
Rothi, Leslie J. Gonzalez,
Fuller, Renee,
Leon, Susan A.,
Kendall, Diane,
Moore, Anna,
Wu, Samuel S.,
Crosson, Bruce,
Heilman, Kenneth M.,
Nadeau, Stephen E.
Six individuals with probable Alzheimer’s disease (AD) participated in a phase 1 study employing a repeated measures, parallel baseline design testing the hypothesis that error-free experience during word production practice combined with an acetyl cholinesterase inhibitor would improve confrontation naming ability. While acetyl cholinesterase inhibitors are safe and delay cognition decline associated with AD, improvement […]
Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders
Vellas, Bruno,
Black, R.,
Thal, Leon J.,
Fox, Nick C.,
Daniels, M.,
McLennan, G.,
Tompkins, C.,
Leibman, C.,
Pomfret, M.,
Grundman, Michael
Background: Immunization of patients with Alzheimer’s disease (AD) with synthetic amyloid-beta peptide (Abeta(42)) (AN1792) was previously studied in a randomized, double-blind, placebo-controlled phase 2a clinical trial, Study AN1792(QS-21)-201. Treatment was discontinued following reports of encephalitis. One year follow-up revealed that AN1792 antibody responders showed improvements in cognitive measures as assessed by the neuropsychological test battery […]